INVO Fertility, Inc.
IVFNasdaq
$1.04
↓ -8.0%Jul 17 close · end-of-day
Price
1Y↓ -98.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.7M
Enterprise Value
$3.6M
P/E
0.0
P/S
0.2
P/B
0.1
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$7.2M
Net Income (TTM)
$35.2M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-105.7%
Net Margin
487.4%
ROE
234.2%
ROIC
-35.6%
Debt / Equity
0.1
Net Cash
-$1.9M
Return 1Y
-99.0%
Company profile
NAYA Biosciences (NASDAQ: NAYA) is a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and fertility.
- CEO
- Steven M. Shum
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 10
- Headquarters
- Florida
- Website
- www.nayabiosciences.com
Earnings
IVF Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$2.0M↑ +23.1%
Diluted EPS-$3.38↓ -99.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.0M | $4.2M | $822,196.00 | $3.0M | $6.5M | $6.8M |
| Gross profit | $948,526.00 | $4.0M | $490,673.00 | — | — | — |
| Operating income | -$5.5M | -$5.2M | -$10.6M | -$6.8M | -$6.6M | -$7.2M |
| Net income | -$8.3M | -$6.7M | -$10.9M | $8.0M | $9.1M | $23.3M |
| Diluted EPS | -$1.52 | -$0.63 | -$17.97 | -$67.37 | -$3,782.65 | -$214.64 |
| Operating cash flow | -$4.8M | -$6.0M | -$6.6M | -$4.8M | -$3.0M | -$7.0M |
| Free cash flow | -$4.8M | -$6.4M | -$6.6M | -$5.2M | -$3.2M | -$7.1M |
| Gross margin | 91.4% | 96.5% | 59.7% | — | — | — |
| Operating margin | -531.7% | -125.4% | -1292.5% | -224.0% | -101.5% | -105.8% |
| Net margin | -804.7% | -160.0% | -1324.8% | 266.0% | 138.6% | 340.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.8M | $1.4M | $1.7M | $1.6M | $1.9M | $1.8M | $1.6M | $2.0M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$1.9M | -$1.3M | -$2.0M | -$1.2M | -$3.0M | -$1.6M | -$1.4M | -$1.6M |
| Net income | -$2.2M | -$1.6M | $14.5M | -$17.4M | -$3.6M | -$3.4M | $47.7M | -$5.5M |
| Diluted EPS | -$22.39 | -$15.11 | -$3,737.60 | -$3,473.93 | -$364.23 | -$39.40 | $3,662.92 | -$3.38 |
| Operating cash flow | -$1.5M | -$640,807.00 | -$617,379.00 | -$3.5M | -$1.7M | -$1.8M | $25,207.00 | -$1.9M |
| Free cash flow | -$1.5M | -$640,807.00 | -$696,253.00 | -$3.6M | -$1.7M | -$1.8M | $13,384.00 | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -100.9% | -90.7% | -116.6% | -73.3% | -160.4% | -93.1% | -89.2% | -78.9% |
| Net margin | -122.2% | -113.8% | 861.6% | -1063.0% | -194.2% | -193.3% | 3015.3% | -274.9% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-12-04 | Szot Matthew K | J | 3 | $0.00 | $0.00 | filing |
| 2025-12-03 | Szot Matthew K | Sale | 4 | $1.52 | $6.08 | filing |
Latest 2 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.